Navigation Links
Medpace Director of Clinical Pharmacology, Jim Wei, MD, PhD, Embarks on a Regulatory Policy Speaking Tour in China in May
Date:5/5/2008

CINCINNATI, May 5 /PRNewswire/ -- Medpace, a leading global full-service contract research organization, announced that Jim Wei, MD, PhD, Medpace Director of Clinical Pharmacology, will address three international conferences in China in May. He will speak at the Impact China IV Conference in Beijing, at the International Workshop on Mass Spectrometry and New Drug Development in Hangzhou, and at the International Society for the Study of Xenobiotics in Shanghai.

At the Impact China IV Conference in Beijing, China on 4-6 May, Dr. Wei will speak on "The Role of Foreign Data and FDA Requirements." In his presentation he will discuss how both pre-clinical and clinical data from foreign countries has increased in Investigational New Drug Application (IND), New Drug Application (NDA), and Biologic License Application (BLA) submissions in the US.

Dr. Wei will talk about "Current FDA Policy and Opportunities for the Chinese Pharmaceutical Industry" at the International Workshop on Mass Spectrometry and New Drug Development in Hangzhou, China on 8-10 May. In his presentation Dr. Wei will discuss regulatory policies that would help Chinese generic suppliers and the opportunities for botanical drug products in the US market.

At the Second Asian Pacific Regional Meeting of the International Society for The Study of Xenobiotics, held in Shanghai, China on 11-13 May, Dr. Wei will speak on the "Current US FDA Recommendations on Drug Interaction Studies and Challenges to the Pharmaceutical Industry." In this presentation he will reveal the challenges to the pharmaceutical industry -- the requirement of the knowledge level of drug metabolism and drug interactions, optimal design of in vitro and in vivo studies, and integrated analyses to assess the risk/benefit ratio of new drugs for potential harmful drug interactions.

Dr. Wei joined Medpace in November 2007 with extensive experience in the clinical trial regulatory aspects of early phase studies. He came to Medpace from the FDA where he served as a Senior Reviewer in the Office of Clinical Pharmacology and was also heavily involved in reviewing INDs and NDAs for the Division of Metabolism and Endocrinology Products.

ABOUT MEDPACE

Medpace is a leading global full-service contract research organization led by top therapeutic and regulatory experts who are driven to further the advancement of pharmaceutical agents for use in cardiology, metabolism, and oncology. Medpace has assembled the industry's most experienced and therapeutically focused team to execute at every level of the company's operations, providing complete and seamless drug development services.

Through specialized regulatory expertise and therapeutically focused clinical operations, Medpace creates strategic partnerships with pharmaceutical and biotechnology companies to provide the most efficient and cost-effective path to drug development -- from program planning and execution to product approval.

With more than 700 employees and clinical trial experience in over 40 countries, Medpace has the global reach and capability to conduct studies and navigate regulatory requirements worldwide within the core therapeutic areas of cardiology, metabolism, and oncology.

Medpace provides centralized image management and reading from Imagepace, centralized laboratory and therapeutically specialized testing from Medpace Reference Laboratories, and Phase I / IIa research services from Medpace Clinical Pharmacology.
Visit the Medpace website at http://www.medpace.com

Contact: John Wynne, 513-579-9911, x2407

j.wynne@medpace.com


'/>"/>
SOURCE Medpace, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Facet Solutions, Inc. Appoints Industry Veteran to Board of Directors
2. Phyhealth Appoints Gerald H. Priceman as Medical Director
3. Halleland Health Consulting Hires New Director of Lifescience Business Development Peter T. Bianco
4. NightHawk Radiology Holdings, Inc. Announces Appointment of David Engert to the Board of Directors
5. Seattle-Based Marsha Rivkin Center for Ovarian Cancer Research Appoints Nancy Sclater, Executive Director
6. Allen Kukovich, Director, Governors Southwest PA Office, Joins Call for Quality Affordable Health Insurance
7. Mentice, Inc. Expands Its North American Sales and Clinical Presence With the Hiring of Jeff Sirek as Director of Educational Sales-East and Sue Landsman as Clinical Applications Manager for the Americas.
8. Executive Director of cbm US congratulates UN on Malaria Campaign
9. Lotus Pharmaceuticals, Inc. Announces Resignation of Director Mel Rothberg
10. US Oncology Welcomes New Director of Federal Government Relations
11. Steris Corporation Announces the Appointment of Two New Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... accreditation with distinction by the Undersea and Hyperbaric Medical Society (UHMS), the leading ... advanced care and patient safety. Only a few hospitals and facilities have earned ...
(Date:12/8/2016)... ... 08, 2016 , ... Mirixa Corporation , a leading ... pharmacist-delivered patient care services, has announced the promotions of Karen Litsinger to senior ... of sales. , Litsinger joined Mirixa in 2008 after serving as a ...
(Date:12/8/2016)... ... December 08, 2016 , ... SunView ... customers and employees that are both engaging and easy to use. Coming off ... the software company revealed today its plans to roll out new AI-powered self-service ...
(Date:12/8/2016)... , ... December 08, 2016 , ... California Senate Bill ... payments per workers’ compensation claim in 2013 and 2014, according to CompScope™ Medical ... Institute (WCRI) . , According to the study, medical payments per claim in California ...
(Date:12/8/2016)... ... December 08, 2016 , ... The Dianne Michael Insurance ... in Hamilton County, is embarking on a charity drive with the aim of ... homes for orphaned or neglected senior dogs in the Cincinnati region, and LuvFurMutts ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... Dec. 9, 2016  Forge Therapeutics, Inc. today ... Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) to advance ... the treatment of bacterial infections including those caused ... as an attractive antibacterial target for more than ... suitable chemical starting points has hampered its progress. ...
(Date:12/8/2016)... , Dec. 8, 2016 Australia Ophthalmic ... new report, "Australia Ophthalmic Lasers Market Outlook to 2022", ... market. The report provides value, in millions of US ... market segements - Excimer Lasers, Femtosecond Lasers and YAG ... distribution shares data for each of these market segements, ...
(Date:12/8/2016)... Dec. 8, 2016 KEY FINDINGS ... Patient warming ... of blood during surgeries, lowering the risks of neurological disorders ... of SSIs. The patient warming systems can be segmented into ... benefits in turn reduce the stay at hospitals thus, lowering ...
Breaking Medicine Technology: